

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 28, 2004.

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California (State or other jurisdiction of incorporation)	1-12830 (Commission File Number)	94-3127919 (IRS Employer Identification No.)
---	-------------------------------------	--

935 Pardee Street
Berkeley, California 94710
(Address of principal executive offices)

(510) 845-9535 (Registrant's
telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

Section 5- Corporate Governance and Management

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On October 28, 2004, the Board of Directors elected Valeta A. Gregg, Ph.D., J.D. to the Board. Dr. Gregg is Vice President & Assistant General Counsel, Patents for Regeneron Pharmaceuticals, Inc., a Tarrytown, New York based company engaged in the development of pharmaceutical products for the treatment of a number of serious medical conditions, including cancer, diseases of the eye, rheumatoid arthritis and other inflammatory conditions, allergies, asthma, and obesity. In her capacity at Regeneron Pharmaceuticals, Dr. Gregg is responsible for company-wide patent-related activities. Prior to joining Regeneron Pharmaceuticals, Dr. Gregg was Senior Patent Attorney for Novo Nordisk of North America.

Dr. Gregg received her J.D. from the University of Colorado School of Law in 1992. She completed her Ph.D. in Biochemistry at the University of Alberta, Edmonton Alberta Canada in 1982 and was a Post-Doctorial Fellow at Columbia University from 1983-1986. Dr. Gregg conducted her undergraduate and graduate studies in Human Nutrition at the University of California at Davis (M.S. 1977; B.S., 1975)

Although the Board has not yet determined whether Dr. Gregg will be appointed to any of its committees, as an independent director, within the meaning of American Stock Exchange Rule 121A, she is eligible to serve on the Board's Audit, Compensation and Nominating Committees.

Dr. Gregg is replacing Jeffrey B. Nickel, Ph.D. on the Board. Dr. Nickel has stepped down in order to focus on his duties as Vice President of Business Development and Marketing. Dr. Nickel was appointed to that position effective June 1, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: November 2, 2004

By /s/ Steven Seinberg

Steven Seinberg,
Chief Financial Officer

Exhibit Numbers	Description
--------------------	-------------

99.1	Press Release dated November 2, 2004
------	--------------------------------------

Valeta A. Gregg, Ph.D., J.D. Joins BioTime, Inc. Board Of Directors

BERKELEY, Calif., Nov. 2 /PRNewswire-FirstCall/ -- BioTime, Inc.

(Amex: BTX) announced today that Valeta A. Gregg, Ph.D., J.D., has been elected to BioTime's Board of Directors. Dr. Gregg currently serves as Vice President & Assistant General Counsel, Patents, for Regeneron Pharmaceuticals, Inc. and will be replacing Jeffrey B. Nickel, Ph.D. on BioTime's Board. Dr. Nickel stepped down in order to focus on his new duties as BioTime's Vice President of Business Development and Marketing.

"Dr. Gregg's strong background as a top patent attorney in the biotechnology and pharmaceutical industries brings additional expertise to our Board of Directors," said Judith Segall, Vice President of Operations and member of the Office of the President at BioTime. "While at Fish & Richardson, P.C. in the mid-1990s, Valeta Gregg provided counsel to the Company and was instrumental in the early development of BioTime's patent portfolio. Her wealth of knowledge in patent law and contributions to the Board will be valuable as BioTime develops and commercializes new products."

Since 2002, Dr. Gregg has been employed at Regeneron Pharmaceuticals, a Tarrytown, New York based company engaged in the development of pharmaceutical products for the treatment of a number of serious medical conditions, including cancer, diseases of the eye, rheumatoid arthritis and other inflammatory conditions, allergies, asthma, and obesity. In her capacity at Regeneron Pharmaceuticals, Dr. Gregg is responsible for company-wide patent-related activities. Prior to joining Regeneron Pharmaceuticals, Dr. Gregg was Senior Patent Attorney for Novo Nordisk of North America.

Dr. Gregg received her J.D. from the University of Colorado School of Law (1992). She completed her Ph.D. in Biochemistry at the University of Alberta, Edmonton Alberta Canada (1982) and was a Post-Doctorial Fellow at Columbia University (1983-1986). She conducted her undergraduate and graduate studies in Human Nutrition at the University of California at Davis (M.S. 1977; B.S., 1975).

About BioTime, Inc.

BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend(R) is manufactured and distributed in the U.S. and Canada by Hospira, Inc. under an exclusive licensing agreement. Information about BioTime can be found on the web at www.biotimeinc.com.

Forward Looking Statements

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; and the price of and demand for BioTime products. Other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

SOURCE BioTime, Inc.

-0- 11/02/2004

/CONTACT: Judith Segall, Vice President of Operations, The Office of the President of BioTime, Inc., +1-510-845-9535; or Lasse Glassen, Investor/Analyst Information of Financial Relations Board, +1-310-854-8313, lglassen@financialrelationsboard.com, for BioTime, Inc./

/Web site: <http://www.biotimeinc.com> /

(BTX)

CO: BioTime, Inc.

ST: California

IN: MTC HEA BIO

SU: PER